PGM3 and Other metabolic disease: PPARA, PPARGC1A, and PPARGC1B (Figures 5D–5F), which are involved in the fatty acid oxidation of PLN-KO hiPSC-CMs, began to decline at day 30, while genes involved in glucose utilization, such as GNPNAT1, PGM3, and GFPT1, were upregulated (Figures 5A–5C), indicating that energy metabolism disorders began to occur.